Premium
Anti‐NeuGcGM3 reactivity: a possible role of natural antibodies and B‐1 cells in tumor immunosurveillance
Author(s) -
RodriguezZhurbenko Nely,
RabadeChediak Maura,
Martinez Darel,
Griñan Tania,
Hernandez Ana Maria
Publication year - 2015
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12827
Subject(s) - immunosurveillance , antibody , immunology , cancer , antigen , cytotoxic t cell , medicine , cancer research , immune system , biology , in vitro , biochemistry
While not naturally expressed in normal human tissues, N ‐glycolylated (NeuGc) gangliosides are overexpressed in several tumors and have immunosuppressive capacity, which contributes to cancer progression. Naturally occurring antibodies against NeuGcGM3 exist in healthy donors that specifically recognize and kill tumor cells expressing the antigen by complement‐dependent and ‐independent mechanisms, the latter resembling an oncotic necrosis–type of cell death. Both the levels of anti‐NeuGcGM3 antibodies in the sera of healthy donors and the percentage of donors with these natural antibodies decrease with age. Our work has shown that anti‐NeuGcGM3 antibodies are not detected in the sera of non‐small cell lung cancer (NSCLC) patients, compared to age‐ and sex‐matched healthy donors, which have anti‐NeuGcGM3. Interestingly, the level of serum total IgM, but not IgG, was significantly lower in cancer patients than in healthy donors. Screening of immortalized mouse splenic and peritoneal‐derived hybridomas showed that peritoneal B‐1 cells secrete anti‐NeuGcGM3 with tumor cytotoxic capacity. Defects in the natural surveillance against tumor antigens could increase the risk of elderly donors developing cancer and affect the capacity of cancer patients to effectively fight against tumor cells.